Data on Dupixent in Eosinophilic Esophagitis Now Published

(MedPage Today) -- Dupilumab (Dupixent) was superior to placebo in the phase III trial underpinning its approval last spring for eosinophilic esophagitis (EoE), researchers said.
About 60% of patients receiving the active drug--a monoclonal...